RxDoctor Payments DataLook up a doctor →

Olwen Hahn, MD

Hematology & Oncology · Chicago, ILNPI 1992823611

Payments from drug & device makers

$11,924,074in general payments, 2019–2025

Across 443 payments — averaging $26,917 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11.6M
  • Seagen Inc.$135K
  • Genentech, Inc.$83K
  • Astrazeneca UK Limited$41K
  • Daiichi Sankyo Inc.$32K
  • F. Hoffmann-la Roche AG$28K
  • plus $5K from 3 others

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer366$11,599,890
Seagen Inc.30$134,990
Genentech, Inc.22$82,729
Astrazeneca UK Limited12$40,911
Daiichi Sankyo Inc.9$31,817
F. Hoffmann-la Roche AG1$28,292
Incyte Corporation1$5,276
Genentech USA, Inc.1$157
Gilead1$12

How this compares

$11,924,074 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$22,456
Medicare patients
89
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →